Although RET alterations are relatively frequent across tumor types, specific targeting of RET in the clinic has been challenging. Ambrogio, Aggarwal and colleagues provide their views on how mechanistic studies have swiftly translated into powerful targeted therapies in two recent clinical studies that led to the FDA approval of selpercatinib for certain tumors in which RET is altered.

中文翻译：

---

编排靶向治疗的 LIBRETTO

尽管 RET 改变在不同肿瘤类型中相对频繁，但临床上 RET 的特异性靶向一直具有挑战性。Ambrogio、Aggarwal 及其同事在最近的两项临床研究中就机制研究如何迅速转化为强大的靶向治疗发表了他们的观点，这两项临床研究导致 FDA 批准 selpercatinib 用于某些 RET 发生改变的肿瘤。